Why Nail Gel Is Banned in Key Markets
Regulators in several regions have moved to ban or restrict nail gel products that contain certain acrylates and photoinitiators linked to skin allergies and occupational health risks. The European Chemicals Agency (ECHA) has identified specific substances in gel formulations that may cause contact dermatitis and respiratory issues when used in poorly ventilated spaces. These restrictions follow a surge in salon complaints and a rise in adverse event reports tied to gel manicure systems. For context on how chemical bans evolve, see the overview at Chemical Watch.
In the United States, the Food and Drug Administration (FDA) has not issued a blanket ban but has flagged products that do not comply with color additive and labeling rules. Several state boards of cosmetology have updated their approved ingredient lists, effectively removing high-risk gel brands from licensed salons. The FDA's guidance on cosmetic safety explains how enforcement actions can function as de facto bans even without a single federal prohibition, as detailed on the agency's site at FDA Cosmetics.
Which Brands and Products Are Affected
Major gel brands such as CND Shellac, OPI GelColor, and IBD have faced reformulation pressure after regulators flagged specific photoinitiators and resin systems. Some professional-grade gels that rely on high-concentration urethane acrylates have been pulled from shelves in jurisdictions with strict chemical restrictions. The bans have forced manufacturers to reformulate or lose access to lucrative salon markets in Europe and parts of Asia.
Startups marketing "free-from" gel alternatives have gained shelf space as legacy brands scramble to meet new standards. Retailers like Sephora and Ulta have updated their private-label gel polish assortments to exclude ingredients on restricted lists. For broader insight into how chemical regulation reshapes consumer markets, see the analysis at Forbes Business Council.
Market and Investor Implications of the Nail Gel Ban
The nail gel ban has created a measurable shift in the professional beauty sector, with sales of traditional gel systems declining in regulated regions while safer alternatives see double-digit growth. Publicly traded personal care companies with exposure to nail products have adjusted R&D spending to prioritize compliance-ready formulations. Investors tracking the sector now weigh regulatory risk alongside traditional metrics like margin and distribution reach.
Private-label gel manufacturers have seen a surge in demand from retailers seeking compliant inventory, reshaping the supply chain for professional and at-home use. The ban also affects ancillary businesses such as UV lamp makers, who must align with new safety standards for curing devices. For a deeper look at how regulatory shifts move capital, see the discussion at U.S. Securities and Exchange Commission.